Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma

Leukemia & Lymphoma ◽

10.1080/10428190701528517 ◽

2007 ◽

Vol 48 (9) ◽

pp. 1736-1744 ◽

Author(s):

Jatin Shah ◽

Wenquan Wang ◽

V. Douglas Harrough ◽

Wayne Saville ◽

Ruby Meredith ◽

...

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Download Full-text

Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Cancer Biotherapy & Radiopharmaceuticals ◽

10.1089/cbr.2005.20.185 ◽

2005 ◽

Vol 20 (2) ◽

pp. 185-188 ◽

Author(s):

Gregory A. Wiseman ◽

Thomas E. Witzig

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Download Full-text

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

Leukemia & Lymphoma ◽

10.1080/10428190500376076 ◽

2006 ◽

Vol 47 (4) ◽

pp. 629-636 ◽

Author(s):

Christos Emmanouilides ◽

Thomas E. Witzig ◽

Leo I. Gordon ◽

Katie Vo ◽

Gregory A. Wiseman ◽

...

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Early Relapse ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Previously Treated ◽

Download Full-text

Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: A new treatment approach for B-cell non-Hodgkin's lymphoma

Drugs of Today ◽

10.1358/dot.2004.40.2.799423 ◽

2004 ◽

Vol 40 (2) ◽

pp. 111 ◽

Author(s):

T.E. Witzig

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

Treatment Approach ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

New Treatment ◽

Download Full-text

Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma

Current Treatment Options in Oncology ◽

10.1007/s11864-002-0027-y ◽

2002 ◽

Vol 3 (4) ◽

pp. 275-282 ◽

Author(s):

Thierry Alcindor ◽

Thomas E. Witzig

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Download Full-text

PCN45 COST COMPARISON BETWEEN 90Y IBRITUMOMAB TIUXETAN CONSOLIDATION AND RITUXIMAB MAINTENANCE POST-CHEMOTHERAPY IN NAÏVE PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)74296-0 ◽

2009 ◽

Vol 12 (7) ◽

pp. A264

Author(s):

JF Tomas ◽

L Febrer ◽

C Piñol ◽

E Musi

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

Cost Comparison ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Rituximab Maintenance ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma

Seminars in Oncology ◽

10.1053/sonc.2002.30148 ◽

2002 ◽

Vol 29 (1) ◽

pp. 87-92 ◽

Author(s):

Leo I Gordon ◽

Thomas E Witzig ◽

Greg A Wiseman ◽

Ian W Flinn ◽

Stewart S Spies ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Low Grade ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Download Full-text

Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature

Clinical Lymphoma ◽

10.3816/clm.2004.n.028 ◽

2004 ◽

Vol 5 (3) ◽

pp. 202-204 ◽

Author(s):

Stephen M. Ansell ◽

Russell J. Schilder ◽

Peter C. Pieslor ◽

Leo I. Gordon ◽

Christos Emmanouilides ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Review Of The Literature ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Download Full-text

Analysis of relationship between baseline body weight and efficacy/safety of yttrium 90 (90Y) ibritumomab tiuxetan radioimmunotherapy in patients (pts) with non-Hodgkin's lymphoma (NHL)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.6700 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 6700-6700

Author(s):

G. A. Wiseman ◽

C. Emmanouilides ◽

K. Vo ◽

R. J. Schilder ◽

P. Foster ◽

...

Keyword(s):

Body Weight ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Baseline Body Weight ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Download Full-text

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s002590000276 ◽

2000 ◽

Vol 27 (7) ◽

pp. 766-777 ◽

Author(s):

Gregory A. Wiseman ◽

Christine A. White ◽

Michael Stabin ◽

William L. Dunn ◽

William Erwin ◽

...

Keyword(s):

Phase I ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Download Full-text

Ongoing Trials with Yttrium 90–Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma

Clinical Lymphoma ◽

10.3816/clm.2004.s.006 ◽

2004 ◽

Vol 5 ◽

pp. S27-S32 ◽

Author(s):

Ivana N.M. Micallef

Keyword(s):

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Download Full-text